SCHEMBL13835692

SCHEMBL13835692

C[CH]OC(=O)Nc1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
ALDH1A1 P00352 4/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP1A1 P04798 2/20 0.53
CA12 O43570 1/20 0.53
BRD4 O60885 1/20 0.53
NR1I2 O75469 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
MB P02144 1/20 0.53
CA3 P07451 1/20 0.53
CYP3A4 P08684 1/20 0.53
RARG P13631 1/20 0.53
TSHR P16473 1/20 0.53
ALOX5AP P20292 1/20 0.53
CA4 P22748 1/20 0.53
CA7 P43166 1/20 0.53
NR1I3 Q14994 1/20 0.53
CA9 Q16790 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL514893 0.85 TDP1 (0.53) MAPTALDH1A1SMN1; SMN2POLBKDM4E
SCHEMBL513776 0.85 SMN1; SMN2 (0.46) MAPTCA12CA1CA2CA9
SCHEMBL2097993 0.83 RAB9A (0.50) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL514410 0.83 MAPT (0.53) MAPTMEN1KMT2ACA12CA1
SCHEMBL482921 0.82 NAPRT (0.52) MAPTALDH1A1MEN1KMT2ATSHR
SCHEMBL9089994 0.79 SMN1; SMN2 (0.69) MAPTALDH1A1MEN1KMT2ACYP1A1
SCHEMBL513489 0.78 KMT2A (0.59) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL514840 0.76 EPHX2 (0.63) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL9125125 0.74 SMN1; SMN2 (0.63) MAPTALDH1A1MEN1KMT2ACYP1A1
SCHEMBL7934328 0.74 SMN1; SMN2 (0.63) MAPTALDH1A1MEN1KMT2ACYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120295866-A1 Synthesis And Use Of Glycoside Pro-Drug Analogs NuTek Pharma Ltd. 2012-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295866-A1 Synthesis And Use Of Glycoside Pro-Drug Analogs GCG, CYP3A5, UGT1A6 MAPT 1411/4885ALDH1A1 1337/4885MEN1 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.